晚期卵巢癌癌性腹水的免疫疗法(英文)

ADOPTIVE IMMUNOTHERAPY OF PATIENTS WITH MALIGNANT ASCITES DUE TO ADVANCED OVARIAN CANCER

本文应用自身的癌性腹水中淋巴细胞体外rIL-2存在下诱导成的LAK细胞与rIL-2,腹腔内联合应用治疗10例晚期卵巢癌癌性腹水患者,其中8例有效,腹水及腹水中肿瘤细胞明显减少,淋巴细胞明显增加。在整个治疗过程中未发现任何副作用,实验治疗后的结果提示,此疗法治疗晚期卵巢癌癌性腹水有效,且安全易行。

Ten patients with malignant ascites due to advanced ovarian cancer were treated by i. p. adoptive transfer of autologous LAK cells induced from lymphocytes in ascites in the presence of rIL-2 and by administration of rIL-2 7 days before and after the transfer of LAK cells. The amount of ascites and the number of tumor cells in ascites was significantly decreased and the number of lymphocytes in ascites was significantly increased in 8 responders, but not in other 2 cases. No changes in the amount of ascites were found in 6 responders during 4 months follow-up after treatment, but increased in other 2 responders. No side effect was encountered in all 10 patients. This preliminary results indicated that treatment was effective, safe and feasible.